Skip to content

Headache & Migraine

Main result

−2.0

Reduction in migraine days (3 months)

Open-Label RCT with Waiting List · Neuropsychiatric Disease and Treatment · Pokladnikova et al. · 2018 · 86 participants

Economic analysis of acupuncture for migraine prophylaxis

Moderate
  • Acupuncture group42 participants
  • Control group44 participants
  • −4.0

    Reduction in migraine days (6 months)

  • 81 %

    Treatment response rate (≥50% reduction)

Study design sheet

  • n=86 participants
  • Economic analysis
Design
Open-Label RCT with Waiting List
Participants
86

n = 86; median of studies with the same design: 79

Duration

3 months of treatment with 6-month follow-up

3 months of treatment with 6-month follow-up

Groups
Each band is proportional to the group’s number of participants, in the order of the list below.
  • Acupuncture group (42)14 acupuncture sessions + standard pharmacotherapy
  • Control group (44)Standard pharmacotherapy only (waiting list)
OBJECTIVE
To evaluate the cost-effectiveness of acupuncture as adjuvant therapy for migraine prevention
WHO
86 patients with migraine, 18-70 years old, minimum 4 migraine days/month
POINTS
Semi-standardized traditional Chinese acupuncture protocol
Results in numbers
  • −2.0Reduction in migraine days (3 months)
  • −4.0Reduction in migraine days (6 months)
  • 81 %Treatment response rate (≥50% reduction)
  • €65.7 vs €131.9Total cost per patient (6 months)
Outcome comparison
  • Total cost after 6 months (€)
    • Acupuncture: 65.7 of 300
    • Control: 131.9 of 300
  • Treatment response rate (%)
    • Acupuncture: 81 of 100
    • Control: 36 of 100

What does this mean for you?

This study showed that adding acupuncture to medication treatment for migraine may be financially attractive in the long term, according to the authors. Although the initial cost is higher due to acupuncture sessions, lost productivity and loss of income tended to be lower in the acupuncture group, but these differences were not statistically significant.

Article summary

Plain-language narrative summary

This prospective economic study evaluated the cost-effectiveness of acupuncture as adjuvant therapy in migraine prophylaxis in the Czech Republic. An open-label randomized clinical trial was conducted comparing acupuncture combined with standard pharmacotherapy versus standard pharmacotherapy alone, with analysis of direct and indirect costs from three perspectives: third-party payer, patient, and society.

The study included 86 patients diagnosed with migraine, ages 18 to 70 years and a minimum of 4 migraine days per month. Participants were randomized to an acupuncture group (n=42) and a waiting-list control group (n=44). The treatment protocol consisted of 14 sessions of semi-standardized acupuncture over 12 weeks, followed by 6 months of follow-up. The primary endpoint was the comparison of total costs between groups, including direct medical costs, direct nonmedical costs, and indirect costs.

The results demonstrated significant clinical efficacy of acupuncture, with a reduction of 2 migraine days after 3 months and 4 days after 6 months of follow-up. The treatment response rate (≥50% reduction in frequency) was 81% in the acupuncture group versus 36% in the control group at 6 months. There was also a significant reduction in symptomatic medication use and improvement in migraine-specific quality of life.

From an economic perspective, although no statistically significant differences were found between the groups, an important trend was observed. During the 3-month treatment period, total costs were higher in the acupuncture group (€696 vs €285) primarily due to costs of sessions and travel. However, at 6-month follow-up, this trend reversed, with lower costs in the acupuncture group (€66 vs €132, p=0.071).

The analysis by perspectives revealed that the more favorable economic trend for acupuncture derived from the reduction of indirect costs, particularly loss of productivity and loss of income, without statistically significant differences. In the acupuncture group, there was a gradual reduction of these costs over time: from €134.3 at baseline to €13.9 at 6 months. From the patient's perspective, direct costs were higher in the acupuncture group, due to the sessions and travel; medication co-payment was also slightly higher (€21.8 vs €11.1 during treatment; €20.7 vs €12.0 at follow-up), and only loss of income was lower at 6 months.

From the third-party payer perspective, a trend toward reduced medication reimbursement costs was observed in the acupuncture group, both during treatment (€25.6 per patient) and during follow-up (€29.3). Emergency department visits related to migraine were also significantly lower during treatment with acupuncture.

This study is pioneering in the economic analysis of acupuncture for migraine in the Czech Republic and one of the few to examine multiple cost categories from different perspectives. The results suggest that, although acupuncture increases initial healthcare costs, the long-term economic benefits, especially in reducing indirect costs, may justify its inclusion as adjuvant therapy in migraine prophylaxis.

Strengths

  • First economic study of acupuncture for migraine in the Czech Republic
  • Comprehensive analysis of direct and indirect costs from multiple perspectives
  • Long-term follow-up (6 months)
  • Semi-standardized acupuncture protocol

Limitations

  • Open-label study without blinding
  • Relatively small sample size
  • Absence of placebo group with sham acupuncture
  • Differences in total costs not statistically significant
Dr. Marcus Yu Bin Pai

Expert Commentary

Clinical Relevance

The question this work answers is not whether acupuncture works for migraine — that is already reasonably established — but whether it is sustainable economically as an adjuvant to prophylactic pharmacotherapy. For those who treat patients with chronic migraine in pain services, this distinction is crucial when justifying therapy to insurers, managers, and supplementary health councils. The profile that benefits is the patient of working age, with high attack frequency, already on prophylactic medication without full response. The reversal of costs observed at 6 months — from €696 to €66 per patient — points to a realistic time window for cost-benefit analysis. This has direct implications on how we structure treatment packages: the 14-session course studied here brought clinical benefit and, according to the authors, the additional cost may be justified by the clinical improvement and, above all, by lower productivity loss and loss of income; from the payer's perspective, however, there was no significant cost difference, and maintenance was not evaluated.

Notable Findings

The 81% response rate in the acupuncture group versus 36% in the control at 6 months is the most robust clinical data, and it is a difference of expressive magnitude for any prophylactic therapy in migraine. Equally noteworthy is the trajectory of indirect costs in the acupuncture group: the drop from €134 to €14 over 6 months is compatible with lower productivity loss, but indirect costs also fell in the control group (from €253 to €60) and the between-group difference was not significant (p=0.075 at 6 months); the authors describe a trend, not a proven effect — even so, it is an outcome that rarely appears in acupuncture clinical trials. The additional reduction in emergency department visits during the treatment period also deserves attention, since these events carry high institutional cost and significant impact on quality of life. The analysis from multiple perspectives — payer, patient, and society — is the most complete approach available in the literature for this indication.

From My Experience

In my practice at the pain clinic, migraine with four or more monthly attacks in an economically active patient is one of the indications in which I most quickly recommend acupuncture as an adjuvant, precisely because the functional impact is disproportionately high. I usually observe perceptible clinical response — reduction in frequency and intensity — from the fourth or fifth session, with a plateau of improvement around the tenth to twelfth session. The 14-session protocol described in this study is compatible with what we use here, with subsequent monthly maintenance in responders. I habitually combine this with counseling on sleep hygiene, trigger management, and, when indicated, adjustment of prophylactic pharmacotherapy. Patients who do not respond after eight sessions with adequate frequency rarely progress — and in this subgroup I review the differential diagnosis before insisting. The data on recovered productivity resonates with what I see clinically: the impact on absenteeism is usually what most motivates adherence to treatment over time.

Dr. Marcus Yu Bin Pai · MD, PhD · Pain Medicine · Physical Medicine and Rehabilitation · Medical Acupuncture

PhD in Health Sciences, University of São Paulo. Board-certified in Pain Medicine, Physical Medicine and Rehabilitation, and Medical Acupuncture.

Full original article

Read the full scientific study

Neuropsychiatric Disease and Treatment · 2018

DOI: 10.2147/NDT.S174870

Access original article

Scientific review

Medical disclaimer: This content is for educational purposes only and does not replace consultation, diagnosis, or treatment by a qualified professional. Some information may be assisted by artificial intelligence and is subject to inaccuracies. Always consult a physician.

Content reviewed by the medical team at CEIMEC — Integrated Centre for Chinese Medicine Studies, a reference in Medical Acupuncture for over 30 years.

  • Strong
  • Moderate
  • Limited
  • Weak
19801990200020102020
This study among the Library’s studiesEach dot is a study: left to right, the publication year; top to bottom, the study design, from meta-analyses to preclinical work; colour and shape give the level of evidence. Highlighted: the Headache & Migraine studies.
See the numbers: This study among the Library’s studies
Study designHeadache & MigraineAll studies
Meta-analysis · Systematic Review23387
RCT15224
Clinical Guideline05
Observational338
Case Series07
Narrative Review7155
Preclinical / Animal06
Other11203
See the Headache & Migraine studies in the Library

Related articles

Based on this article’s categories

  1. Wonderling et al. · BMJ · 2004

    • Headache & Migraine
    • Clinical Trial Methodology
  2. Linde et al. · Cochrane Database of Systematic Reviews · 2009

    • Systematic Reviews & Meta-Analyses
    • Headache & Migraine
  3. Vickers et al. · Health Technology Assessment · 2004

    • Headache & Migraine
    • Clinical Trial Methodology
  4. Facco et al. · Headache · 2008

    • Headache & Migraine
    • TCM Theory & Diagnostics